<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shekhar S</submitter><funding>Norwegian Research Council</funding><pagination>676488</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8089380</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12</volume><pubmed_abstract>Recent studies have identified a clinical isolate of the commensal &lt;i>Streptococcus mitis&lt;/i> that expresses &lt;i>Streptococcus pneumoniae&lt;/i> serotype 5 capsule (&lt;i>S. mitis&lt;/i> serotype 5) and shows serospecificity toward pneumococcal serotype 5. However, it remains unknown whether &lt;i>S. mitis&lt;/i> serotype 5 induces protective immunity against pneumococcal serotype 5. In this study, we evaluated the ability of &lt;i>S. mitis&lt;/i> serotype 5 to generate protective immunity in a mouse model of lung infection with pneumococcal serotype 5. Upon challenge infection with &lt;i>S. pneumoniae&lt;/i> serotype 5, mice intranasally immunized with &lt;i>S. mitis&lt;/i> serotype 5 exhibited reduced pneumococcal loads in the lungs, nasal wash, and bronchoalveolar lavage fluid compared with those receiving PBS (control). The immunized mice displayed significantly higher levels of IgG and IgA antibodies reactive to &lt;i>S. mitis&lt;/i> serotype 5, &lt;i>S. pneumoniae&lt;/i> serotype 5 or &lt;i>S. pneumoniae&lt;/i> serotype 4 than the antibody levels in control mice. In vaccinated mice, the IgG/IgA antibody levels reactive to &lt;i>S. mitis&lt;/i> serotype 5 or S. &lt;i>pneumoniae&lt;/i> serotype 5 were higher than the levels reactive to &lt;i>S. pneumoniae&lt;/i> serotype 4. Furthermore, &lt;i>in-vitro&lt;/i> restimulation of the lung-draining mediastinal lymph node cells and splenocytes from immunized mice with killed &lt;i>S. mitis&lt;/i> serotype 5, &lt;i>S. pneumoniae&lt;/i> serotype 5 or &lt;i>S. pneumoniae&lt;/i> serotype 4 showed enhanced Th17, but not Th1 and Th2, responses. Overall, our findings show that mucosal immunization with &lt;i>S. mitis&lt;/i> serotype 5 protects against &lt;i>S. pneumoniae&lt;/i> serotype 5 infection and induces Th17 and predominant serotype-specific IgG/IgA antibody responses against pneumococcal infection.</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>Vaccination With the Commensal &lt;i>Streptococcus mitis&lt;/i> Expressing Pneumococcal Serotype 5 Capsule Elicits IgG/IgA and Th17 Responses Against &lt;i>Streptococcus pneumoniae&lt;/i>.</pubmed_title><pmcid>PMC8089380</pmcid><funding_grant_id>273833</funding_grant_id><pubmed_authors>Petersen FC</pubmed_authors><pubmed_authors>Amdal HA</pubmed_authors><pubmed_authors>Shekhar S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Vaccination With the Commensal &lt;i>Streptococcus mitis&lt;/i> Expressing Pneumococcal Serotype 5 Capsule Elicits IgG/IgA and Th17 Responses Against &lt;i>Streptococcus pneumoniae&lt;/i>.</name><description>Recent studies have identified a clinical isolate of the commensal &lt;i>Streptococcus mitis&lt;/i> that expresses &lt;i>Streptococcus pneumoniae&lt;/i> serotype 5 capsule (&lt;i>S. mitis&lt;/i> serotype 5) and shows serospecificity toward pneumococcal serotype 5. However, it remains unknown whether &lt;i>S. mitis&lt;/i> serotype 5 induces protective immunity against pneumococcal serotype 5. In this study, we evaluated the ability of &lt;i>S. mitis&lt;/i> serotype 5 to generate protective immunity in a mouse model of lung infection with pneumococcal serotype 5. Upon challenge infection with &lt;i>S. pneumoniae&lt;/i> serotype 5, mice intranasally immunized with &lt;i>S. mitis&lt;/i> serotype 5 exhibited reduced pneumococcal loads in the lungs, nasal wash, and bronchoalveolar lavage fluid compared with those receiving PBS (control). The immunized mice displayed significantly higher levels of IgG and IgA antibodies reactive to &lt;i>S. mitis&lt;/i> serotype 5, &lt;i>S. pneumoniae&lt;/i> serotype 5 or &lt;i>S. pneumoniae&lt;/i> serotype 4 than the antibody levels in control mice. In vaccinated mice, the IgG/IgA antibody levels reactive to &lt;i>S. mitis&lt;/i> serotype 5 or S. &lt;i>pneumoniae&lt;/i> serotype 5 were higher than the levels reactive to &lt;i>S. pneumoniae&lt;/i> serotype 4. Furthermore, &lt;i>in-vitro&lt;/i> restimulation of the lung-draining mediastinal lymph node cells and splenocytes from immunized mice with killed &lt;i>S. mitis&lt;/i> serotype 5, &lt;i>S. pneumoniae&lt;/i> serotype 5 or &lt;i>S. pneumoniae&lt;/i> serotype 4 showed enhanced Th17, but not Th1 and Th2, responses. Overall, our findings show that mucosal immunization with &lt;i>S. mitis&lt;/i> serotype 5 protects against &lt;i>S. pneumoniae&lt;/i> serotype 5 infection and induces Th17 and predominant serotype-specific IgG/IgA antibody responses against pneumococcal infection.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2026-05-08T13:31:04.169Z</modification><creation>2026-04-07T23:59:04.771Z</creation></dates><accession>S-EPMC8089380</accession><cross_references><pubmed>33953733</pubmed><doi>10.3389/fimmu.2021.676488</doi></cross_references></HashMap>